MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
DVA stock logo

DVA

DaVita Inc.

$145.58
-4.76
 (-3.17%)
Exchange:  NYSE
Market Cap:  9.732B
Shares Outstanding:  54.417M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Care Facilities
   
CEO:  Javier J. Rodriguez
Full Time Employees:  76000
Address: 
2000 16th Street
Denver
CO
80202
US
Website:  https://www.davita.com
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/12 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue12,140,14712,815,55013,643,069
Gross Profit3,820,4304,217,0293,684,245
EBITDA2,321,0882,724,7222,642,097
Operating Income1,602,7842,090,4832,010,615
Net Income691,535936,342746,803

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets16,893,57817,285,26817,480,103
Total Liabilities14,150,22815,193,91716,321,664.999
Total Stockholders Equity1,056,097121,122-651,081.999
Total Debt11,116,42112,066,83615,049,989
Cash and Cash Equivalents380,063794,933757,747

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,059,0312,022,0381,886,500
Capital Expenditure-567,985-555,443-575,864
Free Cash Flow1,491,0461,466,5951,310,636
Net Income691,5351,250,7371,078,716
Net Change in Cash125,645415,191-122,078

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)15,657,268.177Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)16,330,990.858Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)15,893,400.700Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)3,095,018.041Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)3,228,194.775Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)3,141,695.048Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)1,565,115.899Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)1,653,063.487Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)1,595,940.328Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,827,925.948Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,906,580.484Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,855,493.513Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)18.120Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)18.760Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)17.770Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
12.816B  ?P/S
 (TTM)
: 
0.72
?Net Income
 (TTM)
: 
936.342M  ?P/E
 (TTM)
: 
17.05
?Enterprise Value
 (TTM)
: 
24.18B  ?EV/FCF
 (TTM)
: 
18.45
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.61  ?ROIC
 (TTM)
: 
0.11
?Net Debt
 (TTM)
: 
11.136B  ?Debt/Equity
 (TTM)
: 
-23.12
?P/B
 (TTM)
: 
-19.56  ?Current Ratio
 (TTM)
: 
1.29

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
11.37Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates DVA intrinsic value between $179.86 – $247.27 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate DVA Intrinsic Value

Common questions about DVA valuation

Is DaVita Inc. (DVA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for DaVita Inc. (DVA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is DVA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DVA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is DVA’s P/E ratio?

You can see DVA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for DVA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is DVA a good long-term investment?

Whether DVA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

DVA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.17
MARKETSnap

Trading Metrics:

Open: 148.63   Previous Close: 150.34
Day Low: 144.77   Day High: 151.19
Year Low: 101   Year High: 159.42
Price Avg 50: 143.04   Price Avg 200: 131.96
Volume: 970561   Average Volume: 1.035M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Should You Buy Warren Buffett's Top 3 Stocks of 2026 So Far?
20-04-2026 04:40
Should You Buy Warren Buffett's Top 3 Stocks of 2026 So Far?
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
15-04-2026 19:02
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know
09-04-2026 19:01
DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
09-04-2026 13:11
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts
02-04-2026 19:01
DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market
30-03-2026 19:17
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read